Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022

Pathogens that Cause Illness Clinically Indistinguishable from Lassa Fever, Nigeria, 2018

Jonathan W. Ashcroft1, Adebola OlayinkaComments to Author , Nnaemeka Ndodo, Kuiama Lewandowski, Martin D. Curran, Chioma Dan Nwafor, Kingsley Madubuike, Helen Bagnall, Abdulmajid S. Musa, Adama Ahmad, Afolabi Akinpelu, Adesola Adeleye, Chukwuji Martin, Adejoke Akano, Michael Onoja, Akanimo Iniobong, Winifred Ukponu, Chinedu Arinze, Else Ilori, Nwando Mba, Benedict Gannon, Anthony Ahumibe, and Chikwe Ihekweazu
Author affiliations: Public Health England, London, UK (J.W. Ashcroft, H. Bagnall, B. Gannon); London School of Hygiene and Tropical Medicine, London (J.W. Ashcroft, H. Bagnall, B. Gannon); Nigeria Centre for Disease Control, Abuja, Nigeria (A. Olayinka, N. Ndodo, C. Dan Nwafor, K. Madubuike, A.S. Musa, A. Ahmad, A. Akinpelu, A. Adeleye, C. Martin, A. Akano, M. Onoja, A. Iniobong, W. Ukponu, C. Arinze, E. Ilori, N. Mba, A. Ahumibe, C. Ihekweazu); Public Health England, Porton Down, UK (K. Lewandowski); Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, UK (M.D. Curran)

Main Article

Table 1

Array and MinION sequencing results for a subset of samples from patients who met the case definition for Lassa fever that were positive for virus, Nigeria, 2018

Sample Kraken hits TAC virus hits Mapping hits Mapped reads, no. (%)
307 None None NA NA
165 Human mastadenovirus B Adenovirus Adenovirus 2 246 (0.07)
349 Yellow fever virus Yellow fever virus Yellow fever virus 66 (0.02)
370 None None NA NA
184 None None NA NA
320 None Epstein-Barr virus Epstein-Barr virus 22 (0.01)
344 None None NA NA
279 Yellow fever Yellow fever Yellow fever virus 72 (0)
157 Pegivirus C (hepatitis G) None Pegivirus C (hepatitis G) 116 (0.01)
147 None Dengue 2 virus Dengue 2 virus 0
322 None None NA NA
70 Lassa virus Lassa virus Lassa virus 16309 (5.05)-L, 8265 (2.575)-S
201 None None NA NA

*MinION described in (5,6). NA, not applicable; TAC, TaqMan Array Cards (Applied Biosystems,

Main Article

  1. McCormick  JB, King  IJ, Webb  PA, Johnson  KM, O’Sullivan  R, Smith  ES, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987;155:44555. DOIPubMedGoogle Scholar
  2. Marongiu  L, Shain  E, Drumright  L, Lillestøl  R, Somasunderam  D, Curran  MD. Analysis of TaqMan Array Cards data by an assumption-free improvement of the maxRatio algorithm is more accurate than the cycle-threshold method. PLoS One. 2016;11:e0165282. DOIPubMedGoogle Scholar
  3. Wood  DE, Lu  J, Langmead  B. Improved metagenomic analysis with Kraken 2. Genome Biol. 2019;20:257. DOIPubMedGoogle Scholar
  4. Li  H, Durbin  R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:58995. DOIPubMedGoogle Scholar
  5. Kafetzopoulou  LE, Pullan  ST, Lemey  P, Suchard  MA, Ehichioya  DU, Pahlmann  M, et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science. 2019;363:747. DOIPubMedGoogle Scholar
  6. Lewandowski  K, Xu  Y, Pullan  ST, Lumley  SF, Foster  D, Sanderson  N, et al. Metagenomic nanopore sequencing of influenza virus direct from clinical respiratory samples. J Clin Microbiol. 2019;58:e0096319. DOIPubMedGoogle Scholar
  7. Shields  A, Patel  S. Infections in the immunocompromised host: primary immunodeficiency disorders. Medicine (Baltimore). 2021;49:60310. DOIGoogle Scholar
  8. Nigeria Centre for Disease Control. An update of yellow fever outbreak in Nigeria [cited 2021 May 1].

Main Article

1Current affiliation: Army, Defence Science & Technology, Ministry of Defence, London, UK.

Page created: February 25, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.